TBP (TATA-Box Binding Protein)
Overview
flowchart TD
TBP["TBP"] -->|"interacts with"| Als["Als"]
TBP["TBP"] -->|"expressed in"| Ms["Ms"]
TBP["TBP"] -->|"regulates"| Alzheimer["Alzheimer"]
TBP["TBP"] -->|"activates"| RELA["RELA"]
TBP["TBP"] -->|"activates"| RHEB["RHEB"]
TBP["TBP"] -->|"activates"| SPI1["SPI1"]
TBP["TBP"] -->|"activates"| HNF4A["HNF4A"]
TBP["TBP"] -->|"activates"| AXIN1["AXIN1"]
TBP["TBP"] -->|"activates"| MYC["MYC"]
TBP["TBP"] -->|"activates"| YWHAZ["YWHAZ"]
TBP["TBP"] -->|"activates"| TXNIP["TXNIP"]
TBP["TBP"] -->|"activates"| EGR1["EGR1"]
TBP["TBP"] -->|"activates"| STAT3["STAT3"]
TBP["TBP"] -->|"activates"| CCND1["CCND1"]
style TBP fill:#4fc3f7,stroke:#333,color:#000
TBP (TATA-Box Binding Protein) is a general transcription factor essential for RNA polymerase II-mediated transcription initiation. Encoded by the TBP gene located on chromosome 6q27, this protein plays a fundamental role in regulating gene expression across all eukaryotic cells. TBP is particularly notable in neurodegeneration research due to its involvement in multiple polyglutamine diseases, most notably spinocerebellar ataxia type 17 (SCA17), and its broader implications in transcriptional dysfunction observed in [Alzheimer's disease](/diseases/alzheimers-disease) and [Huntington's disease](/diseases/huntingtons). [@kikuchi2000]
<div class="infobox infobox-gene">
...TBP (TATA-Box Binding Protein)
Overview
Mermaid diagram (expand to render)
TBP (TATA-Box Binding Protein) is a general transcription factor essential for RNA polymerase II-mediated transcription initiation. Encoded by the TBP gene located on chromosome 6q27, this protein plays a fundamental role in regulating gene expression across all eukaryotic cells. TBP is particularly notable in neurodegeneration research due to its involvement in multiple polyglutamine diseases, most notably spinocerebellar ataxia type 17 (SCA17), and its broader implications in transcriptional dysfunction observed in [Alzheimer's disease](/diseases/alzheimers-disease) and [Huntington's disease](/diseases/huntingtons). [@kikuchi2000]
<div class="infobox infobox-gene">
| Property | Value |
|----------|-------|
| Gene Symbol | TBP |
| Full Name | TATA-Box Binding Protein |
| Chr Location | 6q27 |
| NCBI Gene ID | 6908 |
| OMIM ID | 600075 |
| Ensembl ID | ENSG00000112592 |
| UniProt ID | P20226 |
| Encoded Protein | TATA-Binding Protein |
| Associated Diseases | Huntington's disease, spinocerebellar ataxia type 17, Alzheimer's disease |
</div>
Gene Structure and Molecular Biology
Genomic Organization
The TBP gene spans approximately 32 kb and consists of 8 exons encoding a 339-amino acid protein. The gene contains a polymorphic CAG repeat in the first exon that encodes a polyglutamine (polyQ) tract in the N-terminal domain. This polyQ tract is the critical region implicated in disease pathogenesis.
Protein Structure
The TBP protein contains several distinct functional domains:
- N-terminal domain (aa 1-159): Glutamine-rich region containing the polymorphic polyQ tract. This domain is involved in protein-protein interactions with various transcription cofactors and can undergo post-translational modifications including phosphorylation, sumoylation, and acetylation.
- C-terminal domain (aa 160-339): The conserved "saddle-shaped" DNA-binding domain that binds specifically to the TATA box sequence (TATAAA) in gene promoters. This domain is highly conserved across eukaryotes and is essential for TBP's function as a general transcription factor. [@friedman2008]
Normal Physiological Functions
TBP performs several critical cellular functions:
Transcription Initiation: TBP is the DNA-binding component of the transcription factor IID (TFIID) complex. It binds to the TATA box in promoter regions and facilitates the recruitment of RNA polymerase II and other general transcription factors to form the pre-initiation complex (PIC).
Promoter Recognition: TBP provides promoter specificity by recognizing TATA box-containing genes. Estimates suggest approximately 10-20% of human promoters contain canonical TATA boxes.
Transcriptional Regulation: Beyond basal transcription, TBP interacts with various transcriptional activators and repressors to modulate gene expression in response to cellular signals.
Transcription-Coupled DNA Repair: TBP is involved in the transcription-coupled nucleotide excision repair (TC-NER) pathway, particularly for genes actively transcribed by RNA polymerase II.
Mitochondrial Transcription: TBP also functions in mitochondrial DNA transcription as part of the mitochondrial transcription factor A (TFAM) complex. [@benn2008]Expression Patterns
TBP is ubiquitously expressed as a housekeeping gene, with highest levels in metabolically active tissues:
| Tissue Type | Expression Level |
|-------------|------------------|
| Brain (cortex, hippocampus, cerebellum) | Highest |
| Liver | High |
| Kidney | High |
| Heart | Moderate |
| Skeletal muscle | Moderate |
| Most other tissues | Low-moderate |
In the central nervous system, TBP is expressed in:
- Cortical pyramidal neurons
- Hippocampal pyramidal neurons and granule cells
- Cerebellar Purkinje cells
- Cerebellar granule cells
- Dopaminergic neurons in the substantia nigra
The Allen Brain Atlas demonstrates particularly high TBP expression in neurons with high transcriptional activity, reflecting the protein's essential role in general transcription.
Disease Associations
Spinocerebellar Ataxia Type 17 (SCA17)
SCA17 is caused by CAG repeat expansion in the TBP gene, making it a member of the polyglutamine (polyQ) disease family that includes [Huntington's disease](/diseases/huntingtons), [spinocerebellar ataxia type 1](/diseases/sca1), and several other ataxias.
Molecular Pathogenesis
- Normal repeat range: 25-42 CAG repeats
- Pathogenic range: 45-66+ repeats
- Intermediate range: 43-49 repeats (may cause reduced penetrance)
The expanded polyQ tract leads to:
Protein misfolding: Mutant TBP adopts abnormal conformational states
Aggregation: TBP forms intracellular inclusions and aggregates
Transcriptional dysregulation: Altered TBP function disrupts normal gene expression patterns
Neuronal toxicity: Progressive neurodegeneration in cerebellum and other brain regionsClinical Features
SCA17 presents with:
- Progressive cerebellar ataxia (gait and limb incoordination)
- Dementia and cognitive decline
- Psychiatric symptoms (depression, anxiety, psychosis)
- Extrapyramidal signs (parkinsonism, dystonia)
- Dysarthria and dysphagia
- Variable age of onset (typically 20-50 years)
Recent Research Findings
Recent studies have identified:
- Digenic inheritance: TBP can interact with STUB1 to cause complex ataxia-dementia phenotypes
- CAA interrupt motifs: CAA interruptions within the CAG repeat can modify disease phenotype
- Genetic modifiers: Intermediate repeat expansions may act as modifiers in other spinocerebellar ataxias
[@fung2023]
Huntington's Disease (HD)
Although HD is caused by HTT gene mutations, TBP plays a significant role in HD pathogenesis:
- Transcriptional dysregulation: Mutant huntingtin protein alters TBP function and nuclear localization
- TBP aggregation: TBP is recruited into huntingtin inclusions in HD brains
- Therapeutic target: Restoring proper transcription through TBP modulation is an active research area
Studies have shown that TBP levels and modifications are altered in HD models and patient tissues, suggesting TBP dysfunction contributes to the broader transcriptional dysregulation characteristic of HD. [@govorov2011]
Alzheimer's Disease
TBP involvement in [Alzheimer's disease](/diseases/alzheimers-disease) relates to:
- Transcriptional dysregulation: AD brains show widespread transcriptional changes, with TBP playing a central role in general transcription machinery disruption
- Tau pathology interaction: TBP may interact with pathological tau species, as both are nuclear proteins affected in AD
- Therapeutic implications: Modulating TBP function could potentially restore normal transcriptional patterns in AD
Research using AD brain tissue and models has demonstrated altered TBP post-translational modifications and nuclear import/export dynamics. [@schneider2019]
Parkinson's Disease
TBP has been associated with [Parkinson's disease](/diseases/parkinsons-disease) through:
- Transcriptional dysregulation in dopaminergic neurons
- Possible interactions with alpha-synuclein pathology
- Altered expression in PD brain regions
Post-Translational Modifications in Neurodegeneration
TBP undergoes several modifications relevant to neurodegeneration:
Phosphorylation: TBP phosphorylation affects its DNA-binding activity and interactions with cofactors. Stress-activated kinases can modify TBP in disease contexts.
Sumoylation: TBP can be sumoylated, and this modification is altered in polyglutamine diseases. Sumoylation affects TBP's transcriptional activity and may influence aggregation.
Acetylation: TBP acetylation modulates its function and can be dysregulated in neurodegeneration.[@hsieh2012]
Therapeutic Approaches
Several therapeutic strategies targeting TBP are under investigation:
| Approach | Mechanism | Status |
|----------|-----------|--------|
| Gene silencing | Reduce mutant TBP expression | Preclinical |
| Aggregation inhibitors | Prevent TBP aggregation | Research |
| Transcriptional modulators | Restore normal transcription | Experimental |
| Protein replacement | Deliver functional TBP | Theoretical |
| Small molecule stabilizers | Stabilize normal TBP conformation | Discovery |
The polyglutamine tract makes TBP an attractive target for:
- RNA interference (RNAi) approaches
- Antisense oligonucleotide (ASO) therapy
- CRISPR-based gene editing
- Small molecule chaperones
Interaction Network
TBP interacts with numerous proteins relevant to neurodegeneration:
- TFIID complex components: TAF1, TAF2, TAF4, TAF6, TAF9, TAF10, TAF11, TAF12
- Transcription factors: TFIIA, TFIIB, TFIIE, TFIIF, TFIIH
- Coactivators: p300/CBP, GCN5, PCAF
- Nuclear receptors: steroid hormone receptors
- Polyglutamine disease proteins: huntingtin, ataxin-1, ataxin-3, ataxin-7
- Aggregation-related: SQSTM1/p62, ubiquilin
Research Models
Several model systems have advanced understanding of TBP in neurodegeneration:
- Cell culture: Neuronal and non-neuronal cell lines expressing mutant TBP
- Drosophila: Drosophila models showing polyQ-expanded TBP causes neurodegeneration
- Mouse models: Transgenic mice expressing mutant TBP recapitulate SCA17 phenotype
- Induced neurons: Patient-derived iPSC neurons for disease modeling
[@fujigasaki2001]
See Also
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Huntington's Disease](/diseases/huntingtons)
- [Spinocerebellar Ataxia Type 17](/diseases/sca17)
- [Parkinson's Disease](/diseases/parkinsons-disease)
- [Polyglutamine Diseases](/mechanisms/polyglutamine-diseases)
- [Transcriptional Dysregulation](/mechanisms/transcriptional-dysregulation)
- [Amyloid Hypothesis](/mechanisms/amyloid-hypothesis)
- [Tau Pathology](/mechanisms/tau-pathology)
External Links
- [NCBI Gene: TBP](https://www.ncbi.nlm.nih.gov/gene/6908)
- [UniProt: TBP](https://www.uniprot.org/uniprot/P20226)
- [OMIM: TBP](https://www.omim.org/entry/600075)
- [Allen Brain Atlas](https://brain-map.org/)
- [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
- [Alzheimer's Disease Neuroimaging Initiative](https://adni.loni.usc.edu/)
References
[Kikuchi et al., SCA17 and TBP (2000)](https://doi.org/10.1093/hmg/9.14.2073)
[Friedman et al., TBP in transcription (2008)](https://doi.org/10.1016/S0092-8674(00)81401-4)
[Benn et al., TBP in neurodegeneration (2008)](https://doi.org/10.1093/hmg/ddn250)
[Roy et al., TBP in polyglutamine diseases (2017)](https://doi.org/10.1016/j.tcb.2017.03.005)
[Choudhury et al., TBP aggregation in neurodegeneration (2017)](https://doi.org/10.1093/hmg/ddx120)
[Fung et al., SCA17 genotype-phenotype correlations (2023)](https://doi.org/10.1002/mds.29342)
[Schneider et al., TBP and transcriptional dysregulation in AD (2019)](https://doi.org/10.1186/s13073-019-0623-1)
[Fujigasaki et al., SCA17 transgene models (2001)](https://doi.org/10.1093/hmg/10.23.2721)
[Govorov et al., TBP modifications in HD models (2011)](https://doi.org/10.1016/j.neurobiolaging.2010.09.014)
[Hsieh et al., TBP sumoylation in neurodegeneration (2012)](https://doi.org/10.1074/jbc.M111.306639)Pathway Diagram
The following diagram shows the key molecular relationships involving TBP - TATA-Box Binding Protein discovered through SciDEX knowledge graph analysis:
Mermaid diagram (expand to render)